Rachel Rosovsky
@RosovskyRachel
Followers
921
Following
2K
Media
126
Statuses
470
Hematologist @massgeneralnews
Massachusetts, USA
Joined June 2016
@PERTConsortium @VIVAPhysicians @RosovskyRachel Superb study published in @CircAHA. First RCT in PE in more than a decade. Big step forward!
0
2
3
@RosovskyRachel Presents STORM-PE RCT Results at VIVA 2025 @PERTConsortium
@roblookstein | @Angiologist
https://t.co/Xu6dwRb3rE
#Anticoagulation #DeepVenousThrombosis #DVT #Health #Hematology #Hemostasis #STORM_PE #HemostasisToday #Medicine #PERTConsortium #VIVA2025
0
2
2
#JustPublished: STORM-PE RCT Primary Outcomes @roblookstein @RosovskyRachel
@sahilparikhmd @angiologist @KNagarshethMD
https://t.co/HcMwH00gx0
0
9
19
Thank you @Pertconsortium for partnering with Penumbra on this trial.
Another incredible moment for PE-Storm at #VIVA25! Honored to have partnered with @PenumbraInc on this groundbreaking trial—paving the way for new standards in pulmonary embolism treatment and outcomes. Congratulations @RosovskyRachel @roblookstein
0
1
4
Breaking news! @RosovskyRachel announced the PE- Storm Trial first and secondary results just published.
1
8
17
Thrilled on behalf of all the STORM-PE investigators and patients to share these groundbreaking results. Thank you Circ for simultaneous publication:
ahajournals.org
Background: Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right-to-left-ventricular (RV/LV) diameter ratio and are at risk of early clinical decompensation and...
STORM-PE shows improved functional outcomes for mechanical thrombectomy at discharge and at 90 days @VIVAPhysicians #VIVA25
0
3
14
Thank you Circ for simultaneous publication: https://t.co/98p5nhruMX
ahajournals.org
Background: Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right-to-left-ventricular (RV/LV) diameter ratio and are at risk of early clinical decompensation and...
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Signific...
0
1
2
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Signific...
prnewswire.com
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly...
0
1
9
Thank you VIVA and honored to present our late breaking abstract, STORM-PE 90 days results showing earlier physiological recovery and improvement in 90 day functional status with MT + AC vs AC alone in intermediate high risk PE pts. Thank you Circ for simultaneous publication.
#VIVA25: Rachel Rosovsky outlines further results from the STORM-PE RCT with findings simultaneously published in @CircAHA @VIVAPhysicians
3
7
24
#VIVA25: Rachel Rosovsky outlines further results from the STORM-PE RCT with findings simultaneously published in @CircAHA @VIVAPhysicians
0
4
11
Live @TCTConference @crfheart amazing session today discussing the impact of the #STORM-PE data on the future of #PE care. Thank you @PenVascular for the support of the study.
1
9
43
Patients with acute intermediate-high-risk PE who undergo mechanical thrombectomy have a greater reduction in the RV/LV ratio at 48 hours than those treated with anticoagulation alone, according to results from the first-of-its-kind STORM-PE RCT. #TCT2025
https://t.co/nyyxO7aNH3
0
5
7
The first—and only—RCT proving anticoagulation (AC) works for PE was in 1960 with 73 patients. See how far we've come. At #VIVA2025, on behalf of #STORMPE team & in collaboration #PERTConsortium, I’ll present the first RCT comparing MT + AC vs AC alone for acute
1
2
9
Live @TCTConference First podium presentation of the #STORM-PE trial!! First RCT of thrombectomy vs Anticoag ever!! Thank you to @crfheart @PenVascular @PERTConsortium for advancing the field
2
18
52
Join us in San Diego for the PERT Consortium 2025 Scientific Symposium. Learn and network with experts from all over the world.
Only 3 days left in the PERT 2025 Registration Summer Sale! ☀️Save $100 on PERT 2025 Registration by using code SUMMER100 (Valid 5/23 - 5/30 only) Register now: https://t.co/UvT2W7rNan
0
0
1
We want to learn from you! How do you evaluate heavy menstrual bleeding in patients on anticoagulation. Take our survey: https://t.co/v8FTEuXHv9
@CardioNerds @isth @ASH_hematology @PERTConsortium @thrombosisday @acweyand @bhwords @aswolberg @fnainle
How do you as a medical provider evaluate heavy menstrual bleeding in patients on anticoagulation? Foundation for Women & Girls w/Blood Disorders is interested in identifying ways to improve care for patients with menorrhagia through research survey.
0
5
8
How do you as a medical provider evaluate heavy menstrual bleeding in patients on anticoagulation? Foundation for Women & Girls w/Blood Disorders is interested in identifying ways to improve care for patients with menorrhagia through research survey.
0
2
1
Join us tonight as our Trainee Council members present challenge PE cases from their institutions. Learn from these emerging leaders in the PE space. @FMaeWestMD @jameshorowitzmd @EricSecemskyMD @cardionerds @bhwords @JonnyMoriarty @drandrewsharp @GBarnesMD @klinelabs
Future leaders in PE care, don’t miss this! Join us tomorrow for a webinar designed to meet the clinical practice and professional needs of trainees. Hear from emerging and established leaders on the trainee experience, navigating cases, and thriving as a clinician devoted to
0
1
7
Excited to present in this important topic with Dr. Bader. Learning Theater 2 at CHEST2024. @PERTConsortium
We are excited to host a special satellite session during #CHEST2024 in Boston, Ma, sponsored by The PERT Consortium™ and supported by Penumbra, Inc. Escalating Care in Pulmonary Embolism Patients: The Role of Computer Assisted Vacuum Thrombectomy (CAVT) Register
3
0
2